Scarica l'app Stockscreener
3.15
1.25%
-0.04
Pre-mercato:
3.15
Precedente Chiudi:
$3.19
Aprire:
$3.25
Volume 24 ore:
20,277
Relative Volume:
0.01
Capitalizzazione di mercato:
$6.75M
Reddito:
$743.00K
Utile/perdita netta:
$-7.63M
Rapporto P/E:
-0.253
EPS:
-12.4498
Flusso di cassa netto:
-
1 W Prestazione:
-4.83%
1M Prestazione:
+14.55%
6M Prestazione:
-29.53%
1 anno Prestazione:
-83.93%
Intervallo 1D:
$3.15
$3.25
Intervallo di 1 settimana:
$3.15
$3.40
Portata 52W:
$2.56
$20.00
Can-Fite Biopharma Ltd ADR Stock (CANF) Company Profile
Nome
Can-Fite Biopharma Ltd ADR
Settore
Industria
Telefono
972 3 924 1114
Indirizzo
10 Bareket Street, Kiryat Matalon PO Box 7537, Petah-Tikva
Compare CANF vs VRTX, REGN, ARGX, RVMD, ALNY
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
CANF
Can-Fite Biopharma Ltd ADR
|
3.15 | 6.75M | 743.00K | -7.63M | 0 | -12.45 |
VRTX
Vertex Pharmaceuticals Inc
|
479.00 | 121.16B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
667.17 | 68.78B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
888.82 | 57.44B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
188.07 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.40 | 36.28B | 4.29B | 577.22M | 641.34M | 4.2086 |
Can-Fite Biopharma Ltd ADR Stock (CANF) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2017-08-11 | Iniziato | Maxim Group | Buy |
| 2016-10-19 | Ripresa | ROTH Capital | Buy |
| 2016-08-29 | Ripresa | Rodman & Renshaw | Buy |
| 2015-11-30 | Reiterato | H.C. Wainwright | Buy |
| 2015-03-31 | Reiterato | H.C. Wainwright | Buy |
| 2015-03-30 | Downgrade | ROTH Capital | Buy → Neutral |
| 2014-12-29 | Reiterato | ROTH Capital | Buy |
| 2014-11-18 | Iniziato | H.C. Wainwright | Buy |
Mostra tutto
Can-Fite Biopharma Ltd ADR Borsa (CANF) Ultime notizie
Can-Fite Positive Phase 2a Pancreatic Cancer Study Data Accepted for Presentation at ESMO Congress 2026, One of the World's Premier Scientific Meetings in Oncology - GlobeNewswire Inc.
Can-Fite Secures Australian Patent Allowance Supporting Namodenoson Development and Marketing in Liver and Pancreatic Cancer - Sahm
symbol__ Stock Quote Price and Forecast - CNN
Can-Fite Achieves Key Pivotal Phase 3 Psoriasis Milestone with Completion of Patient Enrolment for the Interim Analysis: Data Expected Q4 2026/Q1 2027 - Sahm
Can-Fite Highlights Survival Outcomes In Pancreatic Cancer Patients - Sahm
Wednesday's session: gap up and gap down stocks - ChartMill
Can Fite Biopharma stock surges 65% on pancreatic cancer data By Investing.com - Investing.com Nigeria
Can Fite Biopharma stock surges 65% on pancreatic cancer data - Investing.com
What's going on in today's pre-market session - ChartMill
Can-Fite BioPharma Ltd. Sponsored ADR Financial Disclosures & SEC Filings - TradingView
Can-Fite BioPharma Ltd. Sponsored ADR Actuals & Estimates (AMEX:CANF) - TradingView
12 Health Care Stocks Moving In Friday's Pre-Market Session - Sahm
Can-Fite BioPharma (NYSEAMERICAN:CANF) jumps after Japan patent update - TechStock²
Can Fite Biopharma stock jumps on Japan patent for obesity drug - Investing.com South Africa
Top movers in Friday's pre-market session - ChartMill
Can-Fite Publishes Peer-Reviewed Scientific Article Demonstrating the Broad Therapeutic Potential of Piclidenoson and Namodenoson - Sahm
Form 6K Can-Fite BioPharma Ltd. For: 22 June By Investing.com - Investing.com South Africa
CANF Stock Price, Quote & Chart - ChartMill
Can-Fite to Present Late-Stage Clinical Pipeline and Licensing Opportunities at BIO International Convention 2026 - Sahm
CANF Technical Analysis | Trend, Signals & Chart Patterns | CAN FITE BIOPHARMA LTD-ADR (NYSEARCA:CANF) - ChartMill
CANFCan-Fite Biopharma Ltd ADR Stock Price and Quote - Finviz
CANF Stock Chart | CAN FITE BIOPHARMA LTD-ADR (NYSEARCA:CANF) - ChartMill
Scientific Publication of Can-Fite and Vetbiolix Validates Piclidenoson’s Potential in the Multi-Billion Dollar Canine Osteoarthritis Market - Sahm
Can Fite Biopharma stock rises on osteoarthritis study publication By Investing.com - Investing.com South Africa
D. Boral Capital upgrades Can-Fite BioPharma stock rating on oncology pipeline progress - Investing.com
What Can-Fite Bio (CANF) is doing that could pay off big later (Rallies Strongly) 2026-05-08Long Term Investing - newser.com
Can-Fite Reports Positive Phase 2a Data with Namodenoson in Pancreatic Cancer; 35% of Patients Remain on Therapy, Including One Beyond 16 Months - ChartMill
CANF Ownership | CAN FITE BIOPHARMA LTD-ADR (NYSEARCA:CANF) - ChartMill
Can Fite Biopharma Ltd ADR (CANF) - Minichart
Can-Fite’s Partner Vetbiolix Completes Enrollment in Phase 2 Osteoarthritis Study in Dogs Treated with Piclidenoson; Data Expected in Q3 2026 - ChartMill
Can-Fite BioPharma (CANF) outlines clinical pipeline, cash runway and key risks - Stock Titan
Can-Fite Reports 2025 Financial Results and Ongoing Clinical Progress Highlighting Positive Data in Phase 2a Pancreatic cancer and 9 Years Cancer-Free Survival in Liver Cancer Patient - ChartMill
Can-Fite reports 2025 loss, raises $4.3 million in March - Investing.com
CANF Earnings History & Surprises | EPS & Revenue Results | CAN FITE BIOPHARMA LTD-ADR (NYSEARCA:CANF) - ChartMill
Can-Fite receives Israeli patent for obesity treatment use - Investing.com
Can-Fite Expands Namodenoson anti-Obesity Franchise with Israeli Patent Allowance - Sahm
12 Health Care Stocks Moving In Wednesday's After-Market Session - Sahm
CANF Stock Soars 20% on Positive Mid-Stage Pancreatic Cancer Data - Finviz
Can-Fite BioPharma raises $4M through warrant exercise - Investing.com
Can-Fite Announces Exercise of Warrants for Approximately $4.0 Million in Gross Proceeds - ChartMill
Can-Fite: Receives Canadian Patent Allowance for Namodenoson as an Anti-Obesity Therapy - ChartMill
H.C. Wainwright raises Can-Fite BioPharma price target to $8 on trial data - Investing.com Nigeria
Can Fite Biopharma stock rises after patient success with liver treatment - Investing.com
Can-Fite BioPharma schedules special shareholder meeting as NYSE American issues non-compliance notice - Investing.com
Can-Fite Completes Patient Enrollment in Phase 2a Pancreatic Cancer Study of Namodenoson - Sahm
Curious about the most active stocks on Friday? - ChartMill
These stocks that are showing activity before the opening bell on Wednesday. - ChartMill
Can-Fite Announces Reverse Split of its Ordinary Shares and ADS Ratio Change - Yahoo Finance
Can-Fite’s Latest Developments of its Advanced Stage Drug Pipeline will be Presented at Noble Capital Markets 21st Annual Emerging Growth Equity Conference - Sahm
Let's uncover which stocks are experiencing notable gaps during today's session. - ChartMill
Top movers in Monday's session - ChartMill
Can-Fite Biopharma Ltd ADR Azioni (CANF) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.97%
0.83%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):